» Articles » PMID: 38414914

A Review of New Concepts in Iron Overload

Overview
Specialty Gastroenterology
Date 2024 Feb 28
PMID 38414914
Authors
Affiliations
Soon will be listed here.
Abstract

Iron overload disorders are conditions that can lead to increased body iron stores and end-organ damage in affected organs. Increased iron deposition most commonly occurs in the liver, heart, endocrine system, joints, and pancreas. Iron overload disorders may be caused by genetic or acquired causes (transfusion, dyserythropoiesis, and chronic liver disease). The gene C282Y homozygous mutation is the most common cause of hereditary hemochromatosis (HH). Other genes implicated in HH include , and . In the past 2 decades, there have been major advances in the understanding of genetic iron overload disorders. Furthermore, new novel techniques to measure iron content in organs noninvasively, as well as new therapeutic options for the treatment of HH, are currently under development. This article focuses on the latest concepts in understanding, diagnosing, and managing genetic iron overload disorders, particularly HH.

Citing Articles

The effects of iron deficient and high iron diets on SARS-CoV-2 lung infection and disease.

Carolin A, Frazer D, Yan K, Bishop C, Tang B, Nguyen W Front Microbiol. 2024; 15:1441495.

PMID: 39296289 PMC: 11408339. DOI: 10.3389/fmicb.2024.1441495.


Manganese transporter SLC30A10 and iron transporters SLC40A1 and SLC11A2 impact dietary manganese absorption.

Prajapati M, Zhang J, Chong G, Chiu L, Mercadante C, Kowalski H bioRxiv. 2024; .

PMID: 39071439 PMC: 11275741. DOI: 10.1101/2024.07.17.603814.

References
1.
Cancado R, Melo M, de Moraes Bastos R, Santos P, Guerra-Shinohara E, Chiattone C . Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study. Eur J Haematol. 2015; 95(6):545-50. DOI: 10.1111/ejh.12530. View

2.
Parrow N, Fleming R . Liver sinusoidal endothelial cells as iron sensors. Blood. 2017; 129(4):397-398. DOI: 10.1182/blood-2016-12-754499. View

3.
Richard F, Van Lier J, Roubert B, Haboubi T, Gohring U, Durrenberger F . Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers. Am J Hematol. 2019; 95(1):68-77. PMC: 6916274. DOI: 10.1002/ajh.25670. View

4.
Brissot P, Brissot E . What's Important and New in Hemochromatosis?. Clin Hematol Int. 2021; 2(4):143-148. PMC: 8432403. DOI: 10.2991/chi.k.200726.001. View

5.
Kowdley K, Brown K, Ahn J, Sundaram V . ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol. 2019; 114(8):1202-1218. DOI: 10.14309/ajg.0000000000000315. View